Article Information
vol. 6 no. 4
Published By
Online ISSN
History
- Received July 7, 2020
- Accepted July 29, 2020
- Published online November 2, 2020.
Copyright & Usage
Copyright ©ERS 2020 This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- David R. Muccino1⇑,
- Alyn H. Morice2,
- Surinder S. Birring3,
- Peter V. Dicpinigaitis4,
- Ian D. Pavord5,
- Christopher Assaid1,
- Huub Jan Kleijn6,
- Azher Hussain1,
- Carmen La Rosa1,
- Lorcan McGarvey7 and
- Jaclyn A. Smith8
- 1Merck & Co., Inc., Kenilworth, NJ, USA
- 2Hull York Medical School, Cottingham, UK
- 3Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, King’s College London, London, UK
- 4Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA
- 5Oxford NIHR Respiratory BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK
- 6Certara Strategic Consulting, Oss, The Netherlands
- 7Wellcome-Wolfson Institute of Experimental Medicine, Queen's University Belfast, Belfast, UK
- 8Division of Infection, Immunity and Respiratory Medicine, University of Manchester and Manchester University NHS Trust, Manchester, UK
- David Muccino, Merck & Co., Inc., PO BOX 2000, Rahway, NJ, USA. E-mail: david.muccino{at}merck.com
Funding
Merck
Article usage
Altmetrics
Vol 6 Issue 4
Table of Contents
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Modelling and simulation for dose selection in phase 3
- Phase 3 study designs
- Patient population and inclusion/exclusion criteria
- Preliminary patient characteristics
- Efficacy outcome measures
- Primary and secondary endpoints
- Safety and tolerability
- Statistical analyses
- Discussion
- Acknowledgements
- Footnotes
- References
- Figures & Data
- Info & Metrics